ZyVersa Therapeutics, Inc. (ZVSA): Nasdaq/NYSE listing notice — ZyVersa receives Nasdaq delisting notice for $1.00 bid price non-compliance

ZyVersa Therapeutics, Inc.

Received Nasdaq notice on June 9, 2023 for failing to maintain $1.00 minimum bid price over 30 consecutive business days.
Has 180 calendar days, until December 6, 2023, to regain compliance by closing at or above $1.00 for 10 consecutive business days.
If not cured, may seek a second 180-day period if it meets other listing standards and notifies intent to cure.
Failure to regain compliance could lead to delisting; company may appeal to Nasdaq hearings panel.
Company states there is no assurance it will regain compliance or secure an extension.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 9, 2023, ZyVersa Therapeutics, Inc. (the “ Company ”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Notice ”). The Notice has no immediate effect on

View on SEC.gov

Browse all listing & compliance notices →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-020803

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.